Maggie Yuen Sells 2,432 Shares of Penumbra (NYSE:PEN) Stock

Penumbra, Inc. (NYSE:PEN) CFO Maggie Yuen sold 2,432 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $342.30, for a total value of $832,473.60. Following the sale, the chief financial officer directly owned 18,353 shares in the company, valued at approximately $6,282,231.90. The trade was a 11.70% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Penumbra Stock Performance

Shares of Penumbra stock opened at $340.56 on Friday. The company has a market capitalization of $13.36 billion, a PE ratio of 75.35, a P/E/G ratio of 2.08 and a beta of 0.81. The company has a 50-day simple moving average of $337.51 and a two-hundred day simple moving average of $294.27. Penumbra, Inc. has a one year low of $221.26 and a one year high of $362.41. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.29 and a current ratio of 6.64.

Penumbra (NYSE:PEN) last released its quarterly earnings results on Tuesday, March 3rd. The company reported $1.18 earnings per share for the quarter, beating analysts’ consensus estimates of $1.12 by $0.06. The business had revenue of $385.39 million for the quarter, compared to analysts’ expectations of $367.18 million. Penumbra had a net margin of 12.66% and a return on equity of 11.41%. The company’s revenue was up 22.2% compared to the same quarter last year. During the same period last year, the business earned $0.97 EPS. Research analysts expect that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on PEN. Leerink Partners lowered Penumbra from a “strong-buy” rating to a “hold” rating in a report on Friday, January 16th. UBS Group reissued a “neutral” rating and issued a $374.00 price target on shares of Penumbra in a report on Thursday, February 26th. BTIG Research lowered Penumbra from a “buy” rating to a “neutral” rating and set a $349.00 price target on the stock. in a research note on Thursday, January 15th. Royal Bank Of Canada lowered shares of Penumbra from an “outperform” rating to a “sector perform” rating and increased their price objective for the company from $355.00 to $374.00 in a research report on Tuesday, January 20th. Finally, Wells Fargo & Company reiterated an “equal weight” rating and issued a $374.00 target price on shares of Penumbra in a research note on Thursday, January 15th. Four research analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $361.69.

Institutional Trading of Penumbra

Several large investors have recently made changes to their positions in PEN. Mather Group LLC. purchased a new position in shares of Penumbra during the third quarter worth $25,000. Larson Financial Group LLC grew its position in Penumbra by 4,100.0% during the 4th quarter. Larson Financial Group LLC now owns 84 shares of the company’s stock worth $26,000 after purchasing an additional 82 shares during the period. CIBC Private Wealth Group LLC raised its stake in shares of Penumbra by 2,700.0% during the 4th quarter. CIBC Private Wealth Group LLC now owns 84 shares of the company’s stock valued at $26,000 after buying an additional 81 shares during the last quarter. Motiv8 Investments LLC acquired a new position in shares of Penumbra in the 4th quarter valued at about $27,000. Finally, Newbridge Financial Services Group Inc. purchased a new stake in shares of Penumbra in the second quarter worth about $30,000. 88.88% of the stock is owned by hedge funds and other institutional investors.

About Penumbra

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.